Background The veterinary sedative xylazine is increasingly found in illicit fentanyl and has been associated with numerous health harms. Xylazine test strips (XTS) are an emerging technology that can theoretically assist consumers in avoiding xylazine, but they require real-world validation. We leverage community-based drug checking program data to compare real-world XTS performance to ‘gold standard’ methods.

Methods Samples were initially assessed by dissolving 1mg of drug product in 1mL water and dipping an XTS (“first generation” Wisebatch™) in the sample. Subsequently, confirmatory testing was performed by sending samples to the National Institute of Standards and Technology for qualitative analysis using direct analysis in real time mass spectrometry (DART-MS). A subset was analyzed quantitatively with liquid chromatography gas spectrometry (LC/MS) to quantify xylazine, fentanyl, and other compounds.

Results Of n=595 fentanyl positive samples, n=333 had both DART-MS and XTS data available. N=69 samples were confirmed to contain xylazine by mass spectrometry, of which the majority contained low concentrations (average concentration 2.3%; 78% of samples contained less than <1% xylazine by weight). Of these, n=34 were correctly identified as positive by xylazine test strips, yielding sensitivity of 49.3%. Of n=264 xylazine negative samples, n=235 were correctly categorized (specificity=89.0%).

Conclusions In our sample, with a large percentage of low-concentration xylazine samples, “first generation” Wisebatch XTS had a relatively low sensitivity, but high specificity. This highlights the value of confirmatory testing and the complicated and often confusing nature of point-of-care test strips for novel substance detection. Follow-up studies are needed.

The authors have declared no competing interest.

JRF received funding from the National Institute on Drug Abuse (DA049644) and the National institute of Mental Health (MH101072). AJK received educational support through the NIH/National Center for Advancing Translational Science (NCATS) UCLA CTSI (TL1TR001883). CLS received support from the National Institute on Drug Abuse (K01DA050771 and R01DA057630). This work was supported by the Centers for Disease Control and Prevention as part of Overdose Data to Action: LOCAL (CDC-RFA-CE-23-0003), and made possible through an equipment grant from the James B. Pendleton Charitable Trust to the UCLA AIDS Institute and UCLA Center for AIDS Research.

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The University of California, Los Angeles Institutional Review Board reviewed and approved this project (protocol IRB-22-0760) and additionally determined that aspects of this work constituted public health surveillance and not human subjects research.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes

The underlying data are sensitive and cannot be shared. However, summary statistics may be provided by the authors upon reasonable request.